Meldola

• Study of ceralasertib plus durvalumab versus docetaxel for patients with advanced or metastatic non-small cell lung cancer Ended recruitment
  2023-509429-37-00 5 2022-10-03 Advanced or Metastatic Non-Small Cell Lung Cancer
• A Phase 3 Study of Rusfertide (PTG-300) in Patients with Polycythemia Vera Ended recruitment
  2023-509750-58-00 5 2022-09-21 Polycythemia Vera
• A Phase 1b Study of Bleximenib in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NP … Ended recruitment
  2023-506582-58-00 3 2022-07-21 Acute Myeloid Leukemia
• A post-trial access roll-over study to allow access to ribociclib (LEE011) for patients who are on ribociclib treatment in Novartis-sponsore … Ended recruitment
  2024-514891-41-00 6 2022-07-19 HR+, HER2- advanced or metastatic breast cancer
• A Global Study to Assess the Effects of Durvalumab with Oleclumab or Durvalumab with Monalizumab Following Concurrent Chemoradiation in Pati … Ended recruitment
  2023-503999-24-00 5 2022-06-01 Patients With Locally Advanced (Stage III), Unresectable Non-small Cel
• A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias … Ended recruitment
  2024-513759-34-00 7 2022-05-31 Relapsed or Refractory Acute Leukemias
• A multicentre phase II, single arm study of Durvalumab (MEDI 4736) with Carboplatin plus Etoposide for 4 cycles followed by Durvalumab maint … Ended recruitment
  2024-516157-41-00 4 2022-05-27 Metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• Phase 3 study of pembrolizumab vs chemotherapy in dMMR advanced or recurrent endometrial carcinoma Ended recruitment
  2023-506361-56-00 5 2022-04-01 Endometrial cancer
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended recruitment
  2023-506771-10-00 5 2022-03-11 Breast Neoplasm, Neoplasm Metastasis
• Study aimed at evaluating the efficacy of the combination of the two drugs, Venetoclax and Azacitidine, on the treatment of patients sufferi … Ended recruitment
  2023-510432-36-00 4 2022-03-01 Acute Myeloid Leukemia with NPM1 mutation
• Clinical trial to compare selinexor pomalidomide dexamethasone combination with elotuzumab pomalidomide dexamethasone in multiple myeloma pa … Ended recruitment
  2024-518304-53-00 5 2022-02-02 Relapsed or Refractory Multiple Myeloma (RRMM)
• Efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia Ended recruitment
  2023-509441-13-00 4 2022-01-31 Warm autoimmune hemolytic anemia
• A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Inoperable or Metastatic Hormone Receptor-positive, HER2-negative Breast Ca … Ended recruitment
  2023-509631-37-00 5 2022-01-18 "Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Bre
• ShorTrip study - Phase II study of Short-course radiotherapy followed by consolidation chemotherapy with the Triplet FOLFOXIRI as total neoa … Ended recruitment
  2024-513297-21-00 4 2022-01-14 Locally advanced rectal cancer
• A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended recruitment
  2024-511599-33-00 5 2021-12-22 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph … Ended recruitment
  2024-511636-27-00 5 2021-12-01 Follicular Lymphoma
• A Clinical Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in … Ended recruitment
  2023-506518-33-00 5 2021-11-10 Locally Advanced or Metastatic Non-Small Cell Lung Cancer
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati … Ended recruitment
  2023-507342-84-00 5 2021-10-26 Bladder Cancer
• Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET Driven, Unresectable and Locally Advanced or Metastatic PRCC … Ended recruitment
  2022-503105-38-00 5 2021-10-22 MET-driven, unresectable and locally advanced or metastatic Papillary
• A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gas … Ended recruitment
  2023-510319-20-00 5 2021-10-21 Gastroesophageal Adenocarcinoma (GEA)
• A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis Ended recruitment
  2024-513605-31-00 4 2021-10-21 Myelofibrosis
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexa … Ended recruitment
  2023-503441-55-00 4 2021-10-14 Relapsed/Refractory Multiple Myeloma
• A Phase 3 Trial of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treat … Ended recruitment
  2023-507698-16-00 5 2021-10-14 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322

Showing 289–312 of 447 trials